Shandong Boan Biotechnology Co Ltd HKEX:6955:
CDE APPROVES PHASE II TRIAL OF ANTI-CD25 ANTIBODY WITH PD-1 INHIBITOR FOR NSCLC
Reuters
Shandong Boan Biotechnology Says CDE Approves Phase II Trial Of Anti-CD25 Antibody With PD-1 Inhibitor For NSCLC
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- HKEX:6955
- Language
- English
Shandong Boan Biotechnology Co Ltd HKEX:6955: